Anticonvulsant drugs in bipolar disorder by Grunze, Heinz et al.
Although much progress has been made in success-
fully treating bipolar disorder, there is increasing
awareness of the limitations of traditional treat-
ment regimens such as lithium and neuroleptics.
The large family of anticonvulsant drugs, however,
appears to be capable of providing new treatment
options, not only as medication of second choice in
patients refractory to treatment, but often as a
treatment standard with high efficacy and low inci-
dence of side effects. Besides established mood sta-
bilizers such as carbamazepine and valproate, new
antiepileptic drugs are entering the field with
promising initial results in the treatment of bipolar
patients. Furthermore, bringing to light the mecha-
nisms of action of anticonvulsants and the similari-
ties between anticonvulsants effective in bipolar
disorder may also deepen our understanding of the
pathophysiological basis of the disorder.
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ecent epidemiological studies on the preva-
lence of bipolar disorder (BD), as defined by the Diag-
nostic and Statistical Manual of Mental Disorders,
IVth edition (DSM IV),
1 have revealed a lifetime preva-
lence of 0.3% to 1.5% across countries.
2 However, there
is increasing awareness that this may be only the tip of the
iceberg.
3 Two large ongoing French studies on the epi-
demiology of mania and depression (EPIMAN and EPI-
DEP, respectively),
4 seek to characterize possible sub-
groups of the bipolar spectrum. One of the preliminary
findings in the EPIMAN study is the relatively high inci-
dence of dysphoric mania (38%). On the other hand, the
EPIDEP study showed that careful screening of patients
revealed in 20% to 30% of the patients, previously diag-
nosed as unipolar depression, a short hypomanic episode,
thus classifying them as bipolar II disorder (BD II) (ie,
BD with hypomanic and depressive episodes) in the Inter-
national Classification of Diseases, Tenth Revision (ICD
10),
5 but not necessarily in DSM IV, where a cutoff point
of four hypomanic days is defined. Inclusion of these
forms of BD is likely to increase the prevalence to 3% to
6 %, which has also been estimated from the studies of
Angst.
6
A meta-analysis of studies published so far reveals that
lithium is only effective in approximately 60% of acutely
manic patients, and probably even less in prophylaxis.
7,8
Lithium appears especially helpful in euphoric mania, but
with atypical forms such as dysphoric mania or mania
within a rapid cycling course, its efficacy rapidly declines.
However, as the epidemiological study of Bourgeois et al
pointed out,
4 these forms of mania, despite being called
atypical, are quite frequent.
In contrast, the antiepileptic drugs carbamazepine (CBZ)
and valproate (VPA) appear more able to cover a broader
spectrum of BD. Their acute antimanic as well as their
prophylactic efficacy appear to be relatively uniform
across subtypes of the disease, with an estimated efficacy
of 50% to 60%. New antiepileptic drugs such as lamotri-
gine (LTG) may add another valuable aspect as an effec-
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Heinz GRUNZEtive treatment for bipolar depression, where most other
mood stabilizers exhibit only small benefit.
9
In order to enrich our possibilities in the treatment of BD,
and to choose the drug appropriate for the specific sympto-
matology and course of disease, we need to know more
about the underlying pathophysiology of the different forms
of disease within the bipolar spectrum and the decisive
mechanisms of action of mood stabilizers. This may also
supply a rationale for the selection of upcoming mood stabi-
lizers for their possible value in treating BD.
Selected abbreviations and acronyms
BD bipolar disorder
BD II bipolar disorder–II (with hypomanic and depressive
episodes)
CBZ carbamazepine
CIBS cocaine-induced behavorial sensitization
ECT electroconvulsive therapy
EPIDEP EPIdemiology of DEPression
EPIMAN EPIdemiology of MANia
GABA γ -aminobutyric acid
GAT-1 γ -aminobutyric plasma membrane transporter
L-5-HTP L-5-hydroxytryptophan
LEG late effector gene
LTG lamotrigine
NGF nerve growth factor 
NMDA N-methyl-D-aspartate
RCBD rapid-cycling bipolar disorder
TRH thyrotropin-releasing hormone
VPA valproate
Accordingly, Stoll and Severus
10 analyzed mood-stabilizing
drugs such as lithium and anticonvulsants for common
modes of action. Their literature search revealed that the
most effective compounds inhibit postsynaptic signal trans-
duction—mainly by decreasing intracellular calcium mobi-
lization—and kindling processes, thus dampening excessive
intra- and intercellular signaling. Besides these common
actions that may also contribute to additive efficacy of the
combination of lithium with different antiepileptic drugs,
anticonvulsants also exert multiple actions on different
receptors of biogenic amines, such as dopamine, serotonin,
glutamate, and γ -aminobutyric acid (GABA). CBZ and VPA
are especially interesting drugs in this respect. This article
gives an overview of the cellular basis of action of anticon-
vulsants, as far as they may contribute to the amelioration of
acute illness and prophylactic efficacy in BD, and reviews
their clinical spectrum and usefulness in BD, in monothera-
py as well as in combination with other drugs, as combining
mood stabilizers may enhance efficacy, but can also possi-
bly multiply side effects.
Mechanism of action of anticonvulsants 
with respect to bipolar disorder
Until the discovery of neuroleptics and lithium in the treatment
of BD, electroconvulsive therapy (ECT) was the only avail-
able—and still is the most effective—treatment of mania. The
antimanic response is estimated to be approximately 80%
11
Although the decisive cellular mechanisms for response remain
speculative, it appears that with every application of ECT the
seizure threshold increases. Thus, ECT has, paradoxically, an
anticonvulsant effect. Interestingly, manic patients show an
increase in seizure threshold with fading manic symptomatol-
ogy.
12 These observations may supply a clinical rationale for
using anticonvulsants in the acute treatment of mania.
When considering the cellular mode of action of anticon-
vulsants, we have to distinguish between three different lev-
els: synaptic transmission, intracellular signaling, and, final-
ly, gene activation. Following this hierarchy, we will first
consider the impact of anticonvulsants on the metabolism
and the synaptic action of biogenic amines.
GABA
Both established mood stabilizers, CBZ and VPA, exhibit
agonistic effects on the GABAergic system. CBZ is a posi-
tive modulator of the GABAA receptor that increases the
GABAAreceptor–mediated chloride current.
13
VPAincreases GABArelease in different areas of the brain.
14
This action of VPA was one of the supporting arguments
leading to a GABA hypothesis of BD.
15-17 However, we are
now facing a situation where we have to note that the most
specific GABAergic anticonvulsants appear not to be as effi-
cacious in BD as drugs with a wider range of action such as
CBZ and VPA. A double-blind randomized trial of
gabapentin
18 could not support antimanic efficacy previous-
ly observed in open trials
19,20 and a first open trial for the 
γ -aminobutyric acid plasma membrane transporter–1 (GAT
1) inhibitor tiagabine also showed no benefit in manic
patients.
21 Another highly specific GABAergic compound,
vigabatrine, is even suspected of inducing affective disorders
and psychosis in epileptic patients.
22
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25Excitatory amino acids
Inhibition of N-methyl-D-aspartate (NMDA) receptor–medi-
ated currents have been reported for CBZ.
23 In addition, a
decrease in aspartate release was observed for VPA.
24 As far
as the new antiepileptic drugs are concerned, much thought
has been given to the inhibition of glutamate and aspartate
release by LTG.
25,26 However, this appears to be more an effect
mediated by the blockade of sodium channels rather than a
direct effect on synthesis and release of excitatory amino
acids. Furthermore, it is still unclear how much this may con-
tribute to antiepileptic potencies of these drugs, and, even
more so, to efficacy in BD. Nevertheless, antiglutamatergic
properties have been at least discussed for LTG as possibly
decisive for antidepressant efficacy in bipolar patients.
27
Dopamine
Catecholamines have been implicated in the pathophysiolo-
gy of affective disorders for more than three decades,
28 either
alone or in the context of a noradrenergic/cholinergic imbal-
ance theory.
29 Whereas anticonvulsants have only little
effect on norepinephrine turnover, their modulatory effect
on dopaminergic transmission is more marked.
In epileptology, the effect of dopamine appears complex and
dependent on receptor specifity and brain area: D2 antago-
nists, eg, neuroleptics, may lower the seizure threshold,
whereas D1 agonists, eg, antiparkinsonian drugs, are also
thought to increase seizure probability.
30 However, epileptic
discharges in the low magnesium model are inhibited by D1
agonists in vitro.
31 In many brain areas, dopamine turnover is
increased by VPA,
32 an effect not seen with CBZ.
33 A
dopamine hypothesis of mania has been proposed by several
authors,
34-36 and, as a matter of fact, mainly dopaminergic-act-
ing neuroleptics such as haloperidol are still one of the first
choices in treating acute mania. Furthermore, recent genetic
findings imply a role of the dopamine D4 receptor gene
37
and the dopamine transporter gene
38,39 in BD.
Although evidence is abundant, the specific role of dopamine
in BD still remains nebulous, due to the lack of clinical expe-
rience with receptor-specific compounds, both in epileptol-
ogy and psychiatry, and the strong secondary interactions of
dopamine with other monoaminergic transmitters.
Serotonin
Although the receptor pharmacology of serotonin is proba-
bly even more complex than that of dopamine, there is great
enthusiasm for attributing a decisive role to serotonin in BD.
Serotonin 1A (5-HT1A) receptor agonists decrease epileptic
discharges in the low magnesium model in vitro.
40 Seroton-
ergic hypofunction has been implied as a major underlying
disturbance in mania.
41 Supporting evidence comes from the
finding of increased platelet serotonin content in mania and
hypomania, compared to unipolar depressed and control sub-
jects.
42 Furthermore, lithium appears capable of increasing
central serotonergic transmission as shown both in the fen-
fluramine stimulation test in remitted bipolar patients,
43 and
by measuring the loudness dependency of the N1/P2 com-
ponent of auditory evoked potentials in patients with affec-
tive disorders.
44,45 In the rat, it also exerts direct effects on 5-
HT1A binding sites in the hippocampus.
46 Regarding
antiepileptic drugs, an increase in extracellular serotonin has
been observed with VPA
47 and CBZ treatment in animal
models,
48 and in vitro with LTG.
49,50 However, at least for
VPA, this may not be decisive for the antiepileptic action, as
VPAstill suppresses seizures in serotonin-depleted mice.
51 In
bipolar patients, however, Maes et al
41 showed by means of
the L-5-hydroxytryptophan (L-5-HTP) test an ameliorating
effect of VPAtreatment on central serotonergic transmission
in manic patients. Unfortunately, due to the small number of
subjects, it was not possible to obtain a significant correla-
tion between clinical treatment response and changes in
serotonergic transmission.
Effects of anticonvulsants on intracellular
messaging systems
Activation of receptors of these biogenic amines initializes
a cascade of intracellular signaling that ultimately leads to
the expression of early genes. Anticonvulsants may, howev-
er, interfere with this cascade on different levels of the sig-
naling pathways, either intracellularly or by blocking trans-
membraneous ionic fluxes. In particular, a disturbed
intracellular calcium homeostasis may be a final common
pathway in BD.
52,53
At the presynaptic terminal, mobilization of calcium stores,
both intracellular and by influx of extracellular calcium
mainly through voltage-gated calcium channels, regulates
neurotransmitter release by presynaptic facilitation and by
controlling the fusion and exocytosis of neurotransmitter
vesicles. On the postsynaptic side, calcium mobilization is
essential for adenylyl cyclase and protein kinase C activa-
tion, and thus for many enzymatic processes, and, ultimate-
ly, early gene activation. Postsynaptic early gene activation,
in turn, modulates the expression of enzymes, receptors, and
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other proteins involved in neuronal transmission, thus also
affecting the presynaptic terminal (Figure 1,next page).
Increased intracellular calcium concentrations, under base-
line conditions or after mobilization following specific stim-
ulation paradigms, have been described in platelets and lym-
phocytes of bipolar patients, in both manic and depressive
episodes.
54 Slightly elevated intracellular calcium release
increases the metabolism of the cell to a maximum, probably
resembling hyperexcitability in mania as a clinical correlate.
However, high levels of intracellular calcium can dampen the
activity of the cell in at least two major ways, by inhibition
of Na/K adenosine triphosphatase (ATPase)
55 and of adeny-
lyl cyclase,
52 thus slowing down the metabolic rate again. An
analogue to depression has been suggested for this state. It
should be noted that some authors also suggest a special sen-
sitivity of Na/K ATPase in bipolar patients to calmodulin and
calcium,
56 which would enhance these effects. Finally, exces-
sive intracellular calcium causes cell death by activating cal-
cium-dependent proteases and phospholipase A. Thus, calci-
um is an essential and, in excess, potentially cytotoxic
component in all major signal transduction pathways: the
cyclic adenosine monophosphate (cAMP) system, the inosi-
tyl/triphosphate-diacylglycerol (IP3-DAG) system, and the
arachidonic acid system (Figure 2,next page).
57
In conclusion, this hypothesis combines special potential fac-
tors of vulnerability in bipolar patients, such as altered Na/K
ATPase and adenylyl cyclase activity (probably on a genetic
basis), with the multiplying effects of increased intracellular
calcium mobilization or calcium influx into the cell. 
Potentially beneficial effects of anticonvulsants through
interference with intracellular calcium signaling are report-
ed at various cellular levels.
A decreased Na/K ATPase activity has been described as a
state marker in acutely ill bipolar patients, as it is not seen
in healthy relatives.
58 Besides lithium, CBZ is also capable
of stimulating Na/K ATPase, measured as rubidium 86
uptake into synaptosomes
59 causing a reduction in intracel-
lular calcium.
Like lithium, CBZ also reduces the activity of protein kinase
A and C by reducing cAMP-dependent protein phosphory-
lation. This also, in turn, reduces the gene expression of pro-
teins responsible for neurotransmission.
60
However, anticonvulsants may also affect voltage-dependent
calcium channels directly. CBZ exerts strong calcium chan-
nel antagonism in vitro, synergistic with verapamil, thus
making an action on L-type calcium channels likely.
61
Similar findings are also true for VPA, which seems to exert
calcium-antagonistic effects through blockade of another
voltage-dependent calcium channel, the T channel.
62 The two
new antiepileptic drugs gabapentin and LTG also exert cal-
cium-antagonistic effects.
63-67 It has to be said, however, that
in another study both CBZ and VPA, in therapeutic concen-
trations, appeared not to affect calcium currents in neocorti-
cal neurons in vitro.
68 Thus, a special aberration of intracel-
lular calcium regulation, as assumed for bipolar patients,
may be a prerequisite for the calcium-antagonistic action of
these antiepileptic drugs in man.
In addition, other actions on ionic currents that may be espe-
cially important for suppression of seizures by CBZ, VPA,
and LTG include inhibition of voltage-dependent sodium
channels,
69,70 and an increase in an early transient potassium
outward current.
71-73
Table I (page 29) summarizes the modes of action on the
synaptic and cytoplasmic levels of some anticonvulsants
commonly used as mood stabilizers.
Sensitization and kindling—behavioral 
models explaining the recurrence 
of bipolar disorder?
Although many aspects of unipolar depression find their
equivalent in behavioral animal studies, eg, learned help-
lessness paradigms or olfactory bulbectomized rats, it still
appears difficult to explain characteristics of BD, such as
swings of mood and increased vulnerability in the course of
the disease, in terms of an integrative model. Although still
speculative in some aspects, sensitization and kindling as
described by Post et al
74 may be helpful in understanding the
course of BD, starting from a molecular level and evolving
towards behavioral changes.
Kraepelin
75 had already noticed in 1921 that a marked psy-
chosocial stressor usually preceded the first affective
episode, whereas subsequent episodes showed minor or
even absent notable life events. At the same time, the fre-
quency of episodes tends to increase, in some patients to the
point of autonomous rapid cycling, with decreasing effica-
cy of mood-stabilizing drugs. 
Post and Contel
76 developed the model of cocaine-induced
behavioral sensitization (CIBS). Cocaine administration
causes hyperlocomotion in rats and hypomanic-like symp-
toms in man. Repeated cocaine administration, however,
may cause a shift of symptomatology toward signs of dys-
phoric mania (which has a high incidence in BD, as shown
by the EPIMAN study) or even paranoid symptoms. Lesion-
ing experiments in the amygdala show that CIBS involves
different neuromodulatory changes depending on the dura-Clinical research
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Figure 1. Schematic representation of the synaptic action of biogenic
amines (norepinephrine, dopamine, and serotonin). Amino
acids, tyrosine, and tryptophan are metabolized by a hydrox-
ylase and a decarboxylase to their respective biogenic
amines, and stored in vesicles. After release into the synap-
tic cleft, these molecules can follow three different paths: 
  Activation of the postsynaptic receptor side. Mediated by
a G-protein, this will activate adenylyl cyclase, breaking
down ATP to ADP and cAMP, which, in turn, migrates into
the nucleus and activates early gene expression;   Activa-
tion of a presynaptic autoreceptor, leading to reduction of
further release of the neurotransmitter;   Presynaptic reup-
take of the transmitter, which may either be restored in vesi-
cles or broken down into inactive metabolic end products by
the monoamine oxidase before excretion. AA, amino acid;
BA, biogenic amines; DC, decarboxylase; H, hydroxilase;
MAO, monoamine oxidase; PAS, presynaptic autoreceptor;
POS, postsynaptic receptor.
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Figure 2. Graphic representation of the three major intracellular pathways, the cAMP system, the IP3-DAG system, and the arachidonic acid sys-
tem. G0 and Gs, G-protein receptors; IP3-DAG, inositol 1,4,5-triphosphate-diacylglycerol; PKC protein kinase C; PLA, phospholipase A;
PLC, phospholipase C.
Modified from ref 57: Schwartz JH, Kandel ER. Synaptic transmission mediated by second messengers. In: Kandel ER, Schwartz JH, Jessell TM, eds. Prin-
ciples of Neural Science. 3rd ed. Norwalk, Conn: Appleton & Lange; 1991:174. Copyright © 1991, Appleton & Lange. With permission.
28tion and frequency of cocaine administration. Thus, not only
the symptomatology can shift, but also the neuronal path-
ways involved, becoming independent of a direct action on
the amygdala. Furthermore, cocaine is also capable of influ-
encing neuromodulators in a similar fashion to stress, ie, by
causing an increase in CRF, ACTH, cortisol, cytokines, cat-
echolamines, and indolamines. 
Relating these findings to intracellular transcriptional
processes, another important analogy to stress sensitiza-
tion can be noted. Both conditions, CIBS and repeated
stress, lead at the end of the intracellular signal-transduc-
ing cascade to the expression of immediate early genes 
(c-fos and zif-268) in the amygdala and related limbic
structures as well as late effector genes (LEG).
77 The com-
position of early genes and their occupation of the activa-
tor protein–1 (AP-1) receptor is partially specific for dif-
ferent stressors, eg, electroconvulsive seizures or cocaine,
as well as for mode of application, ie, acute, repetitive or
chronic.
78,79 This may provide a molecular background for
speculation as to why psychosocial stressors may be more
likely to cause symptoms of depression, whereas others,
like acute pain, do not. Whereas activation of early imme-
diate genes primarily induces expression of genes, such as
neurotransmitter transporter genes, and finally modulates
the acute symptomatology, induction of LEGs such as neu-
rotropins and nerve growth factor (NGF) will modulate
synaptic connectivity and nerve end sprouting, thereby
giving rise to neuroanatomical changes.
Taken together, CIBS is a useful model to study acute
events and long-term changes in symptomatology caused
by episodes of affective disorders. However, to explain the
aspect of sequential unfolding of episodes with increasing
autonomy from the stressor, the amygdala-kindled rat
appears to be a more suitable model. Kindling reflects a
cumulative and progressive unfolding of physiological and
behavioral changes in response to repeated stimulation
over time that eventuates in seizures, initially triggered
then occurring spontaneously.
80 Although epileptic
seizures may have some mechanisms in common with
affective disorders, eg, increased transmembranous cal-
cium fluxes,
81 we are aware that they clearly are two dif-
ferent conditions. However, the rough anatomical sub-
strate is similar, as the amygdaloid complex plays a key
role in both diseases. Repeated electrical stimulation of the
basolateral amygdala decreases the threshold for epileptic
seizures, often leading to spontaneous epileptic activity.
The correlate on the synaptic level is an increase in both
NMDA- and non-NMDA-receptor–mediated glutamater-
gic transmission with a parallel decrease in inhibitory
GABAergic transmission.
82 At the level of expression of
early genes and neuropeptides, an increase in c-fos and
thyrotropin-releasing hormone (TRH) mRNA was
observed.
83 With full manifestation of seizures, these
changes at the synaptic level and of substrate expression
also involve the contralateral, nonstimulated amygdala
complex. It is assumed that, like electrical kindling, recur-
rent affective episodes cause analogous long-term changes
in neuronal networks, such as lowering the threshold for
any consecutive episode. This hypothesis is backed up by
a clinical study by Goldberg and Harrow.
84 Although hav-
ing a comparable total number of episodes before, patients
who had a pattern of close periodicity of episodes showed
an increased relapse risk during follow-up, interpreted as
an indicator of a previous kindling process.
Different drugs useful in BD exert antikindling potencies,
such as lithium, nimodipine, and different anticonvulsants,
eg, CBZ, VPA, and LTG. However, they can all induce tol-
erance, leading to insufficient suppression of seizures in
the kindling model.
85 At the clinical level, this may corre-
spond to tolerance or drug resistance observed with long-
term treatment and/or discontinuation of lithium, CBZ,
and VPA, as seen in some bipolar patients.
86,87
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Table I. Anticonvulsants used as mood stabilizers and their proposed
mode of action.
Substance Main modes of action
Carbamazepine    Inhibition of voltage-gated sodium, pota-
sium and calcium (L) channels 
   GABAergic, adenosinergic, serotonergic,
and glutamate antagonistic properties
Valproate    Increase in potassium outward current
   Inhibition of voltage-gated sodium and 
calcium (T) channels 
   GABAergic and serotonergic properties
Lamotrigine    Increase in potassium outward current
   Inhibition of voltage-gated sodium 
and calcium channels
   Inhibition of glutamate release and 
serotonin reuptake
Gabapentin    Inhibition of sodium and calcium 
channels (possibly)
   Indirect GABAergic properties (possibly)
29Clinical research
30
(Table II) 
Study Design Diagnosis Duration Agents Efficacy
Ballenger & Post
92 Double-blind Manic, SA 11-56 days Carbamazepine (n=10) 7/10 marked improvement
1978 ABA-design Placebo (crossover)
Okuma et al,
94 Double-blind Manic (ICD-9) 6 weeks Carbamazepine (n=32) 21/30 (70%) improved on CBZ
1979 Chlorpromazine (n=28) 15/25 (60%) improved on CPZ
Fewer side effects on CBZ
Slightly faster onset with CPZ
Grossi et al,
95 Double-blind Manic (DSM-III) 21 days Carbamazepine (n=18) 10/15 improved on CBZ
1984 Chlorpromazine (n=19) 10/17 improved on CPZ
Fewer side effects on CBZ
Slightly faster onset with CPZ
Klein et al,
96 Double-blind "Excited psychosis" 5 weeks  Haloperidol +  13/23 (57%) improved on 
1984 RDC: mania,  carbamazepine (n=23) CBZ+HAL
excited SA/S Haloperidol + placebo 11/20 (55%) improved on 
(n=20) HAL+PLC
Müller & Stoll,
97 Randomized Mania 14 days Oxcarbazepine (n=10) OXCBZ ≈ HLD
1984 Haloperidol (n=10) BRMS scores decreased in both
groups 
Faster onset with OXCBZ
Emrich et al,
98 Double-blind Manic (ICD-9) variable Oxcarbazepine (n=7) OXCBZ ≈ VPA
1985 ABA-design Valproate (n=5) OXCBZ > PLC
Placebo (crossover) VPA > PLC
Gonçalves & Stoll,
99 Double-blind Manic, SA 3 weeks Carbamazepine (n=6) CBZ > PLC  
1985 Placebo (n=6)
Lenzi et al,
100 Double-blind Excited 3 weeks Carbamazepine + CBZ + CPZ ≈ LI + CPZ
1986 psychosis chlorpromazine (n=15) Significant improvement on CGI 
Lithium +  (BPRS) in both groups
chlorpromazine (n=15) CBZ group required less CPZ
CBZ group: less paranoia, EPS
Stoll et al,
101  Randomized Manic (ICD-9), SA 3 weeks Carbamazepine (n=29) 12/14 (86%) improved on CBZ
1986 Haloperidol (n=29) 12/18 (67%) improved on HAL
CBZ ≥ HAL
Desai et al,
102 Double-blind Manic 4 weeks Carbamazepine + CBZ + LI > PLC + LI
1987 lithium (n=5)
Placebo + lithium (n=5)
Lerer et al,
103 Double-blind Manic (DSM-III) 4 weeks Lithium (n=19) LI ≥ CBZ
1987 Carbamazepine (n=15)Anticonvulsant drugs in bipolar disorder - Grunze et al Dialogues in Clinical Neuroscience - Vol 1- No.1
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Study Design Diagnosis Duration Agents Efficacy
Lusznat et al,
104 Double-blind Manic/hypomanic 6 weeks Lithium (n=27) LI ≈ CBZ (efficacy)
(1988) Carbamazepine (n=27) LI ≥ CBZ (comedication, 
depression scores)
Okuma et al,
105 Double-blind Manic 6 weeks Carbamazepine (n=103) 50% improved 
1988 Placebo (n=98) on CBZ
30% improved 
on PLC
Brown et al,
106 Double-blind  Mania (DSM-III) 4 weeks Carbamazepine (n=8) 6/8 (75%) marked 
1989 Haloperidol (n=9) improvement on CBZ
2/9 (33%) marked
improvement on HAL
Möller et al,
107 Double-blind Manic/SA  3 weeks Haloperidol + HLD + CBZ ≈ HAL + PLC (efficacy)
1989 (RDC, ICD-9) carbamazepine (n=11) HLD + CBZ ≥ HAL + PLC
Haloperidol +  (comedication)
placebo (n=9)
Emrich,
108 Double-blind  Manic 15 days Oxcarbazepine (n=19) OXCBZ ≈ HLD (efficacy)
1990 Haloperidol (n=19) OXCBZ ≥ HLD (side effects)
Emrich,
108  Double-blind Manic 15 days Oxcarbazepine (n=28) OXCBZ ≈ LI (efficacy)
1990 Lithium (n=24) LI ≥ OXCBZ (side effects)
Okuma et al,
109 Double-blind Manic (ICD-9) 4 weeks Carbamazepine (n=51) 31/51 (62%) improved on CBZ
1990 Lithium (n=54) 30/54 (59%) improved on LI
LI ≈ CBZ
Small et al,
110 Double-blind Manic (DSM-III-R)  8 weeks Carbamazepine (n=24) 8/24 improved on CBZ
1991 Lithium (n=24) 8/24 improved on LI
CBZ ≈ LI 
TABLE II.  Controlled studies of carbamazepine and oxcarbazepine in acute mania. 
ABA, off-on-off design; BPRS, Brief Psychiatric Rating Scale; BRMS, Bech-Raefelson Mania Scale; CBZ, carbamazepine; CGI, Global Clin-
ical Impression scale; CPZ, chlorpromazine; DSM-III, Diagnostic and Statistical Manual of Mental Disorders–III; DSM-III-R, Revised; EPS,
extrapyramidal symptoms; HAL, haloperidol; ICD-9, International Classification of Diseases–9; LI, lithium; PLC, placebo; OXCBZ, oxcar-
bazepine; RDC, Research Diagnostic Criteria; S, schizophrenic; SA, schizoaffective; VAL, valproate; >, significantly better; ≥ , slightly bet-
ter; ≈ , no difference.
Modified from ref 93.
(Table II, continued) 
The clinical issue: spectrum of efficacy of 
anticonvulsants in bipolar disorder
Carbamazepine and oxcarbazepine
In the 60s and early 70s, antiaggressive and emotionally sta-
bilizing features had been observed with phenytoin and
CBZ, both in epileptic patients and otherwise emotionally
disturbed populations.
88-90 These reports, together with
observed antikindling potencies in the animal model, initiat-
ed independent trials of the effects of CBZ in bipolar patients
both in Japan and the US.
91,92
Since then, 19 controlled studies (Table II) have been con-
ducted on the antimanic efficacy of CBZ and its derivative,32
oxcarbazepine. Comparison was made with lithium (6 stud-
ies), neuroleptics (6 studies), and placebo (2 as a parallel arm
study, 2 in an A-B-Asubstituting design of the active drug).
In addition, three trials tested CBZ versus placebo as an add-
on to active treatment. A meta-analysis of these studies by
Post et al
93 gave an overall improvement rate of 61%
(123/203) for CBZ-treated patients, and 86% for oxcar-
bazepine.
93 However, only six trials did not allow coadmin-
istration of neuroleptics and/or lithium. In those method-
ologically unconfounded studies, CBZ was still effective in
50% of manic patients (defined as an at least 50% reduction
of manic symptoms).
111 Those studies gave the general
impression that, in contrast to lithium, CBZ may successful-
ly cover a wider field of different subtypes of bipolar disor-
der, such as schizomanic states, mixed mania, or rapid
cycling patients.
7
In all studies, CBZ showed superiority compared with place-
bo. Assigning lithium as the gold standard, CBZ showed in
five out of six studies efficacy at least equal to that of lithi-
um in classic mania. Compared to neuroleptics (six studies),
equal efficacy was observed for CBZ in four studies, and in
two studies, CBZ appeared more efficient. When using CBZ
in mania, the aim is to reach sufficient plasma levels quick-
ly and ensure reliable intake of the medication. This can 
be done by using a suspension formulation of CBZ. Initial-
ly, 20 mL (400 mg) can be used, followed by 10 mL 3 to 4
times daily.
112 This regimen quickly achieves serum concen-
trations considered sufficient for antiepileptic treatment 
(4-12 µ g/mL). Interestingly, although CBZ has been used in
BD for a long time, no attempt has yet been made to estab-
lish reliable serum concentrations for antimanic efficacy.
As far as side effects are concerned, initial sedation and atax-
ia are often seen with CBZ, especially when used as an anti-
manic loading therapy. These effects are mainly due to the
metabolite 10,1-CBZ-epoxide. These side effects appear
much less often with oxcarbazepine, due to the different
route of metabolism. Autoinduction and heteroinduction of
metabolism also lead to decreased serum levels during con-
tinuation treatment and to changes in serum levels of con-
comitantly used drugs whose metabolism also uses the 3A4
isoform of cytochrome P450. This needs to be kept in mind,
especially when combining CBZ with VPA, haloperidol, and
some antidepressants, or with concomitant use of hormonal
contraceptives.
113,114
Carbamazepine in depression
Data on the antidepressant efficacy of CBZ are clearly
much less robust than those relating to its use in mania.
Additionally, they are confounded by the methodological
problem that these studies mostly included both unipolar
and bipolar depressed patients. Ameta-analysis of all open
studies suggests an antidepressant effect in 55% of
patients (both uni- and bipolar), and in 44% in all con-
trolled studies.
93 However, due to the small samples of
patients, especially in the controlled trials, and the mixing
with unipolar depressed patients, it has been impossible to
prove the antidepressant effects of CBZ so far. If these
exist at all, they appear to be less pronounced than the
antimanic properties.
Carbamazepine in prophylaxis
The benefits of CBZ in BD with regard to possible pro-
phylactic efficacy—in addition to its antimanic action—
had been considered as far back as 1973 in a controlled
study by Okuma et al.
91 In the following years, five double-
blind randomized trials against lithium were carried out,
111
but only one against placebo,
115 which reported a 60%
response rate compared to 22% for placebo after 1 year.
Those earlier studies against lithium suggest a comparable
prophylactic efficacy. However, all these studies suffer
from the methodological shortcoming of short observation
periods. A recent study by Greil et al
116 in 144 patients had
a more appropriate observation period of 2.5 years. Forty-
seven percent of CBZ-completers experienced a relapse
compared to 28% of lithium-completers, a significant out-
come in favor of lithium. Extending this analysis to a basis
of 171 patients divided into classic BD (BD I without
mood-incongruent delusions and without comorbidity)
and nonclassic BD (BD II, mood-incongruent delusions,
comorbidity), lithium was clearly superior in the classic
BD patients; CBZ, however, appeared favorable in the
nonclassic group.
117 Another recent controlled study
showed a higher efficacy for lithium, especially in con-
trolling manic relapses.
118 However, all of these studies
have been conducted over relatively small observation
periods in selected patient populations and may not reflect
naturalistic clinical conditions. An extensive prospective
5-year follow-up of patients in a lithium clinic was
recently published.
119 It revealed that, in the end, only 23%
of patients derived real benefit, meaning that no relapse
and no discontinuation due to side effects occurred during
prophylactic lithium treatment. Similarly, a retrospective
study by Frankenburg et al
120 in patients receiving CBZ for
3 to 4 years revealed that only 18% remained stable on
CBZ alone. Besides problems of compliance, it has been
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Study Design Diagnosis Duration Agents Efficacy
Emrich et al,
15 Double-blind Manic Valproate (n=5) 4/5 marked improvement
1980 ABA-design Placebo
Brennan et al,
124 Double-blind Manic Valproate (n=8) 6/8 (75%) marked 
1984 ABA-design Placebo improvement on VPA
Pope et al,
126 Double-blind Manic (DSM-III) 1-3 weeks Valproate (n=17) 53% improved on VPA
1991 Placebo (n=19) 11% improved on LDC
VPA > PLC
Freeman et al,
125 Double-blind Manic (DSM-III-R) 3 weeks Lithium (n=13) LI: 12/13; VPA: 9/14
1992 Valproate (n=14) LI ≈ VPA
Bowden et al,
127  Double-blind Manic (RDC) 21 days Lithium (n=35) LI: 49% response rate
1994 Valproate (n=68) VPA: 48% response rate
Placebo (n=73) PLC: 25% response rate
LI > PLC; VPA > PLC
LI ≈ VPA
McElroy et al,
130 Randomized Manic with  7 days Valproate (n=21) VPA ≈ HAL
1996 psychotic symptoms Haloperidol (n=15)
Müller-Oerlinghausen  Double-blind Manic (ICD-10) 21 days Valproate (n=69) or VPA + HAL: 67% response rate
and Retzow,
128 Placebo (n=67) as PLC + HAL: 50% response rate
1997 add-on to haloperidol Significantly less HAL needed
in the VPA group
TABLE III. Controlled studies of valproate in acute mania. ABA, off-on-off design; DSM–III, Diagnostic and Statistical Manual of Mental Disor-
ders–III; DSM-III-R, Revised; HAL, haloperidol; ICD-10, International Classification of Diseases, Tenth Revision. LI, lithium; PLC,
placebo; RDC, Research Diagnostic Criteria; VPA, valproate; >, significantly better; ≥ , slightly better; ≈ , no difference.
Modified from ref 127.
suggested that tolerance and discontinuation-induced
refractoriness may add to the decreasing efficacy in long-
term prophylaxis, both for lithium and CBZ.
86
Research on prophylactic efficacy may be conducted
more easily in patients with rapid cycling bipolar disorder
(RCBD), as even with shorter observation periods the nat-
ural course of the disease would predict a fair chance of
relapses and recurrences. Twenty open and three con-
trolled studies support the prophylactic efficacy of CBZ
in RCBD.
121 Only one open study, which, however,
included more patients (n=215) than all the other studies
together, refuted the utility of CBZ in the prophylaxis of
RCBD.
122 However, it should be kept in mind that RCBD
may represent an entity biologically different from BD,
with a low frequency of recurrence. 
In summary, even though prophylaxis with CBZ has a more
favorable outcome than the natural course of the disorder,
more research into the prophylactic efficacy of mood stabi-
lizers remains top of the agenda.
Valproate
Valproate in mania
The treatment of acute manic episodes remains, to this day,
the major indication of VPA in bipolar patients. The first
reports on mood-stabilizing properties came from a French
group using the VPA derivative dipropylacetamide.
123 Soon
afterwards, the first open trials on VPA in mania were con-
ducted, both in Europe
15 and the US
124 (Table III), where
33mostly divalproex was used, an equimolar mixture of sodi-
um VPA and valproic acid that may cause fewer gastroin-
testinal side effects. Antimanic efficacy has been reported in
open studies with a combined total of more than 1000
patients, and has been definitely confirmed by several con-
trolled double-blind studies.
125,126
The largest study that finally obtained Food and Drug
Administration (FDA) approval for VPAin mania was con-
ducted by Bowden et al.
127 These authors tested the anti-
manic potency of VPA in 179 patients against lithium and
placebo. Forty-eight percent of the VPA and 49% of the
lithium patients (compared to 25% for placebo) showed an
at least 50% symptom reduction after 21 days of treatment.
Both VPA and lithium were significantly superior to place-
bo (P=0.004 for VPA). Similar favorable results were
reported by the European study group
128 where VPA was
compared in a double-blind fashion with placebo as an
adjunct to neuroleptic treatment (Table III).
Summarizing the experiences of those trials, it appears that
VPAis effective in a broader spectrum of mania than lithium.
In the study of Bowden et al,
127 it was noted that VPA was
equally effective in mania in RCBD patients. Compared to
lithium, VPA also seems superior in mixed states with coex-
istence of a neurological disease, a history of head trauma,
substance abuse, or anxiety disorders.
129 To date, there is only
one controlled study for anticonvulsants concentrating on psy-
chotic features in mania,
130 in which VPA showed equal effi-
cacy to haloperidol. 
A great advantage of VPA in the treatment of mania is its
wide therapeutic window, allowing a loading therapy strat-
egy. With a dosage of 20 mg/kg/day, therapeutic plasma 
levels can be reached already on the first day. It appears 
that 50 µ g/mL is the threshold serum concentration for
antimanic efficacy.
131 Recent observations have shown that
intravenous VPA loading may even shorten the delay of
antimanic response.
132 Dose-related adverse effects of VPA
include sedation, nausea, diarrhea, asthenia, and thrombo-
cytopenia, but these are usually mild and controllable by
dosage adjustment.
127Taken together, VPA appears to be an
effective and well-controllable treatment of acute mania.
Today, it is considered in many treatment guidelines,
besides lithium, as first-choice treatment for acute mania,
especially in atypical cases.
133-135
Valproate in depression
As with CBZ, the body of evidence in favor of the antide-
pressant efficacy of VPAis rather small compared to mania.
A meta-analysis of open trials suggests an antidepressant
efficacy of VPAin 25% of patients (35/138).
93As a matter of
fact, this figure is not much different from the placebo
response rate usually observed. However, summarizing tri-
als in RCBD patients, 45% showed an acute antidepressant
response in open studies.
136
Valproate in prophylaxis
Open studies using VPA either alone or as an add-on to
lithium have suggested a possible prophylactic efficacy.
A meta-analysis of 11 open studies showed a response
rate of 64% among 496 patients.
137 In RCBD, data from
Calabrese et al
138 from 101 patients suggest good prophy-
lactic efficacy of VPA during the observation period of
17 months. Patients who initially presented with a mixed
episode had the greatest benefit: 94% stayed relapse-free,
compared to 72% with pure mania and 33% of the
depressed patients. In view of the unconvincing data in
support of the prophylactic efficacy of lithium and the
controversial data for CBZ, VPA, despite the lack of con-
trolled trials, remains the current first-line treatment in
the prophylaxis of RCBD. 
Only recently, initial double-blind controlled findings have
been released on the prophylactic efficacy of VPAcompared
to lithium and placebo in BD in general.
139 In this study
including 372 patients, VPA showed advantages in sec-
ondary, but not primary, outcome measures compared to
both lithium and placebo. However, several questions
remain open. The main drawback is again the short study
duration of 1 year, which makes it difficult to assess the
long-term benefit of VPA.We therefore will have to wait a
few more years before getting a better picture of the pro-
phylactic efficacy of VPA. 
The new generation of anticonvulsants
Lamotrigine
Compared to the older antiepileptic drugs, much more
enthusiasm has arisen from the latest generation of anticon-
vulsants, lamotrigine (LTG), gabapentin, and, more recent-
ly, topiramate and tiagabine.
LTG in particular has become a major focus of attention as
it shares many cellular mechanisms of action with the
established mood stabilizers CBZ and VPA. Whereas the
use of LTG in acute mania is limited by the need for slow
titration, initial single case reports
140 and open studies
141,142
34
Clinical researchhave suggested good prophylactic efficacy. Most impor-
tant, these open trials pointed towards efficacy in difficult-
to-treat conditions such as bipolar depression and rapid
cycling. Asmall double-blind trial at the National Institute
of Mental Health (NIMH)
18 confirmed the antidepressant
effect of LTG, with 48% of patients responding after 6
weeks compared to 20% in the placebo group. The most
favorable response was seen in BD I depressed patients
(about two thirds of patients), whereas less than one third
of unipolar depressed patients improved. Recently, this
antidepressant efficacy was verified in a large multicenter
study in 192 patients who showed statistically significant
improvement of bipolar depression with 200 mg LTG,
compared to placebo.
9
Controlled, double-blind multicenter studies on the prophy-
lactic efficacy of LTG, especially in RCBD, are still ongo-
ing. Like other anticonvulsants, LTG may also have benefi-
cial effects in the prophylaxis of schizoaffective disorder.
143
Gabapentin
Like LTG, the introduction of gabapentin stirred up much
enthusiasm. This derivative of GABA appeared to be very
well tolerated, and open studies supported beneficial effects in
mania,
19,20,144 bipolar depression,
145 and prophylaxis.
146 Double-
blind clinical trials for all three indications are still ongoing.
However, at least in bipolar depression, gabapentin seemed
not to be superior to placebo in a small controlled trial.
18
Topiramate and tiagabine
Very recently, preliminary findings from open trials on the
potential benefits of topiramate in BD have become avail-
able. First synthezised in 1990, topiramate belongs to a
new class of antiepileptics, the sulfamate-substituted
monosaccharides. Topiramate shows cellular mechanisms
of action similar to those of established antiepileptic
drugs, namely blockade of voltage-dependent sodium
influx, as well as GABAergic and antiglutamatergic
effects.
147 Observations from McElroy et al
148 and Cal-
abrese et al
149 suggest at least moderate antimanic effica-
cy, and from the observations of Marcotte and Gullick,
150
also possible efficacy in prophylaxis of RCBD. However,
conclusions are still premature as long as the results of
ongoing controlled trials are not in. Fewer data are avail-
able on the GABA transporter inhibitor tiagabine. In an
open trial in 10 manic patients, no antimanic response
was observed despite high dosing.
21
Upcoming candidates
Among anticonvulsants that have been released very recent-
ly or are currently in the last stages of clinical testing, losig-
amone and retigabine appear to have potential as future can-
didates for use in BD, based on their basic mechanisms of
action. Retigabine in particular shows strong antikindling
effects.
151 Felbamate is unlikely to be routinely used in bipo-
lar patients due to its possible severe side effects, especially
acute hepatic necrosis.
152
Older anticonvulsants with potential 
benefits in bipolar disorder
Clonazepam
In neurology, the 7-nitrobenzodiazepin derivative clon-
azepam is used in treating myoclonic and epileptic absence.
In BD, clonazepam was tested for antimanic efficacy in three
double-blind trials
153-155 as monotherapy against lithium,
placebo, or lorazepam. Clonazepam appeared superior to
placebo and as efficient as lithium, but less efficient than
lorazepam. This suggests that the main effect of clonazepam,
and probably of benzodiazepines in general, may be an ini-
tial calming of the patient, which also results in a reduction
in scores in mania rating scales. A longer-lasting effect on
core manic symptoms cannot be concluded from those stud-
ies, as they were only of short duration (maximum 14 days)
and carried out in a small number of patients. Beneficial
effects of clonazepam in the short-term control of agitation
in manic patients were also found in an open study of Bottai
et al
156 where the manic symptomatology was rated in a time-
blind fashion and retrospectively correlated with plasma lev-
els. The initial plasma levels that led to sufficient control of
agitation were in the range of 18.9 to 34.0 µ g/L. Chouinard
et al
157 also conducted a double-blind trial with clonazepam
IM compared to haloperidol IM as initial treatment of agi-
tated manic patients and reported equal efficacy with fewer,
especially extrapyramidal, side effects.
Only two controlled studies have been conducted on the pro-
phylaxis of recurrence of BD, with disappointing results.
Sachs et al
158 compared clonazepam with haloperidol as an
add-on to lithium prophylaxis. No significant difference was
observed between the small groups (n=6 randomized to each
treatment) after 12 weeks, however, 3 out of 6 patients on
clonazepam still needed additional haloperidol. The other
trial, by Aronson et al,
159 was prematurely discontinued after
the first 5 patients enrolled relapsed after 2 to 15 weeks. 
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35In summary, clonazepam may be an effective treatment, like
other benzodiazepines, for rapid control of manic agitation;
however, its medium- and long-term efficacy, especially
against core manic symptoms, cannot be concluded from the
trials so far.
Phenytoin
The efficacy of phenytoin in patients with affective disorders
has not yet been investigated systematically. Earlier anecdo-
tal reports showed an effect on mood and hostility in popu-
lations with aggressive behavior
88,89 and neurotically
depressed patients.
160 Not all of these results could be repli-
cated in further case reports, so that these findings remain
controversial. In contrast, one case report suggests that
phenytoin induces organic mania.
161
In a currently ongoing open trial, we are attempting to char-
acterize potential benefits in manic patients receiving high
oral loading doses of phenytoin (600-1000 mg/d for 3 days,
then tapering down according to plasma level). Preliminary
results in the first 5 patients included suggest good tolera-
bility and an initial beneficial effect on manic agitation; how-
ever, the effect appears transient and leaves other core manic
symptoms unchanged.
Barbiturate anticonvulsants
Besides phenytoin, barbiturates are another group of anti-
convulsants that has not received much attention in the treat-
ment of BD. The only open trial on effects of primidone and
mephobarbital comes from Hayes,
162 who described a sus-
tained positive effect on the course of illness with primidone
in one third of patients (9/27) having previously failed on
standard treatment regimens. Clearly, this group of sub-
stances is still an unexplored field in bipolar disorder, but
should be followed up as an alternative in refractory patients.
Acetazolamide
The carbonic anhydrase inhibitor acetazolamide is used as
an add-on medication in some treatment-refractory epilep-
sies. Hayes
163 reported on 16 bipolar patients who failed to
remain stable on standard mood stabilizers. Addition of
acetazolamide, however, resulted in improved prophylactic
efficacy in 7 out of 16 patients (44%). Unfortunately, the
usefulness of carbonic anhydrase inhibitors in BD has not
been followed up since then.
Combining mood stabilizers 
In clinical practice, anticonvulsants are often used in combi-
nation treatment with lithium and/or neuroleptics in patients
that have been refractory to the first-line treatment. In these
cases, increased efficacy may be obtained, but attention
should be paid to possible side effects occurring in combi-
nation treatment. These issues have recently been extensive-
ly reviewed by Freeman and Stoll.
164 Data suggesting that
combined treatment with lithium increases the efficacy both
of VPA and CBZ appear to be relatively firm; for the new
generation of anticonvulsants, gabapentin and lamotrigine,
only preliminary observations are available. The addition of
LTG to lithium may be an efficacious approach, especially
in the treatment of bipolar depression.
141 Whereas combina-
tion of lithium with VPA, gabapentin, and LTG appears rel-
atively safe, there have been reports of increased neurotoxi-
city with concomitant lithium-CBZ treatment. Such a
combination should especially be avoided in patients with
preexisting central nervous system disease.
165 However, this
judgment may include a bias as the number of patients
receiving CBZ together with lithium exceeds by far any
other lithium/anticonvulsant combination therapy; thus,
reports of side effects become much more likely.
Combinations within anticonvulsants, although in many
cases effective, should be administered only with rigorous
control of plasma levels, as CBZ, VPA, and LTG interfere
with each other's metabolism. Through cytochrome P450
3A, CBZ induces both autometabolism as well as metabo-
lism of VPA. CBZ also increases the metabolism of LTG,
whereas VPAslows it down.
147  ❏
Starting from 1998, the original work of the authors described in this arti-
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Mecanismo de acción e indicaciones de
los anticonvulsivos en el tratamiento de
los trastornos bipolares
A pesar de los grandes progresos que se han realizado
en el tratamiento exitoso de los trastornos bipolares, se
tiene  una mayor conciencia de los límites de los proto-
colos terapéuticos tradicionales tales como el litio y los
neurolépticos.Sin embargo,la gran familia de fármacos
anticonvulsivos parece ser capaz de agregar opciones
terapéuticas,no solo como medicación de segunda elec-
ción en pacientes refractarios al tratamiento,sino como
tratamiento estándard con una alta eficacia y una baja
incidencia de efectos secundarios.Además de los regu-
ladores del humor tales como la carbamazepina y el
valproato,aparecen nuevos fármacos antiepilépticos en
la práctica clínica con  prometedores resultados ini-
ciales  en el tratamiento de los pacientes bipolares.Más
aún,el esclarecer los mecanismos de acción de los anti-
convulsivos y las semejanzas entre los diferentes fár-
macos eficaces en los trastornos bipolares, puede tam-
bién ayudarnos en la comprensión de las bases
fisiopatológicas de dicho trastorno.
Mécanismes d’action et indications 
des anticonvulsivants dans 
le traitement de la maladie bipolaire
Bien que beaucoup de progrès aient été faits dans le
traitement de la maladie bipolaire,les thérapeutiques tra-
ditionnelles telles que le lithium et les neuroleptiques
montrent progressivement leurs limites. Un choix
thérapeutique supplémentaire s’ouvre avec la grande
famille des anticonvulsivants, non seulement comme
traitement de recours pour les patients réfractaires aux
thérapeutiques classiques,mais aussi comme traitement
standard d’une grande efficacité entraînant peu d’effets
secondaires. En plus des stabilisateurs de l’humeur
avérés tels la carbamazépine ou le valproate, de nou-
velles molécules antiépileptiques font leur entrée dans le
traitement de la maladie bipolaire avec des résultats ini-
tiaux prometteurs. En outre, la mise en lumière des
mécanismes d’action des anticonvulsivants et les simili-
tudes présentées par ceux qui sont efficaces dans la ma-
ladie bipolaire devrait permettre d’approfondir notre
compréhension de la physiopathologie de la maladie.
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